Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin
Food intake was recorded during this period
ABSTRACT: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide/GLP-1 RAs are common therapies for managing diabetes and obesity, but gastrointestinal (GI) adverse effects (AEs) such as nausea, vomiting, diarrhea, and constipation frequently limit therapy
Lower doses may still activate GLP-1 receptors, but appetite suppression tends to scale with dose intensity
US$ 28.18
US$ 27.25
US$ 29.66
US$ 29.19
US$ 27.08
US$ 26.86
